Toxicity Evaluation of a VLP-Based Vaccine Аgainst Human Rotavirus Infection Following a Single Administration in Rats: Serum Biochemistry and Histopathological Examination of Organs and Injection Site

Authors

  • Oleg V. Ledenev Department of Biology, Lomonosov Moscow State University, Leninskie Gory, 119234 Moscow, Russia https://orcid.org/0009-0008-6772-1298
  • Ilya E. Filatov National Research Center for Epidemiology and Microbiology named after the honorary academician N. F. Gamaleya, 18 Gamaleya St., 123098 Moscow, Russia https://orcid.org/0000-0001-5274-224X
  • Olesya V. Eliseeva National Research Center for Epidemiology and Microbiology named after the honorary academician N. F. Gamaleya, 18 Gamaleya St., 123098 Moscow, Russia https://orcid.org/0000-0002-0723-9749
  • Oleg E. Latyshev National Research Center for Epidemiology and Microbiology named after the honorary academician N. F. Gamaleya, 18 Gamaleya St., 123098 Moscow, Russia https://orcid.org/0000-0003-1934-9635
  • Igor A. Dyachenko Branch of the Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 6 Nauki Avenue, 142290 Pushchino, Russia https://orcid.org/0000-0002-3053-2804
  • Gulsara A. Slashcheva Branch of the Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 6 Nauki Avenue, 142290 Pushchino, Russia https://orcid.org/0000-0002-4422-487X
  • Elvira R. Shaykhutdinova Branch of the Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 6 Nauki Avenue, 142290 Pushchino, Russia https://orcid.org/0000-0003-2768-4978
  • Ekaterina N. Kazakova Branch of the Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 6 Nauki Avenue, 142290 Pushchino, Russia https://orcid.org/0009-0002-4885-1069
  • Elena S. Sadovnikova Branch of the Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 6 Nauki Avenue, 142290 Pushchino, Russia https://orcid.org/0000-0002-5193-4343
  • Olga I. Patsap Scientific and Educational Resource Center for Innovative Technologies of Immunophenotyping, Digital Spatial Profiling and Ultrastructural Analysis (Molecular Morphology), Peoples' Friendship University of Russia, Moscow, str. Miklukho-Maklaya, 6 https://orcid.org/0000-0003-4620-3922
  • Varvara V. Lebedeva National Research Center for Epidemiology and Microbiology named after the honorary academician N. F. Gamaleya, 18 Gamaleya St., 123098 Moscow, Russia https://orcid.org/0000-0002-3088-0403
  • Arkady N. Murashev Branch of the Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 6 Nauki Avenue, 142290 Pushchino, Russia https://orcid.org/0000-0002-2279-9285
  • Tatiana V. Grebennikova National Research Center for Epidemiology and Microbiology named after the honorary academician N. F. Gamaleya, 18 Gamaleya St., 123098 Moscow, Russia https://orcid.org/0000-0002-6141-9361

Abstract

Virus-like particle (VLP) - based vaccines exhibit outstanding clinical, epidemiological, and immunological efficacy and specificity. The novel technology used for producing their active component without incorporating live viruses enables both injectable and non-injectable (e.g., intranasal) administration, emphasizing the need for a comprehensive safety assessment. This study is part of a preclinical toxicological evaluation program aimed at assessing the safety profile of the “Gam-VLP-rota” vaccine candidate targeting human rotavirus infection.

The goal of this extended toxicology study was to confirm the safety of a single intramuscular administration of the vaccine in Sprague-Dawley rats. The study focused on identifying possible adverse effects both acutely (within 24 hours post-administration) and after a 14-day recovery period, aiming to detect delayed toxicological signs. Toxicological endpoints included evaluation of target organs, coagulation parameters, hematology, clinical biochemistry, necropsy findings, and histopathological analysis.

This article presents a segment of the results, including changes in serum biochemical parameters after a single immunization and histological examination of internal organs and the injection site in rats.

Keywords: VLP; vaccines; preclinical studies; vaccine safety; toxicological chemistry.

Keywords:

VLP, vaccines, preclinical studies, vaccine safety, toxicological chemistry

DOI

https://doi.org/10.22270/jddt.v15i8.7314

Author Biographies

Oleg V. Ledenev , Department of Biology, Lomonosov Moscow State University, Leninskie Gory, 119234 Moscow, Russia

National Research Center for Epidemiology and Microbiology named after the honorary academician N. F. Gamaleya, 18 Gamaleya St., 123098 Moscow, Russia

Ilya E. Filatov , National Research Center for Epidemiology and Microbiology named after the honorary academician N. F. Gamaleya, 18 Gamaleya St., 123098 Moscow, Russia

National Research Center for Epidemiology and Microbiology named after the honorary academician N. F. Gamaleya, 18 Gamaleya St., 123098 Moscow, Russia

Olesya V. Eliseeva , National Research Center for Epidemiology and Microbiology named after the honorary academician N. F. Gamaleya, 18 Gamaleya St., 123098 Moscow, Russia

National Research Center for Epidemiology and Microbiology named after the honorary academician N. F. Gamaleya, 18 Gamaleya St., 123098 Moscow, Russia

Oleg E. Latyshev , National Research Center for Epidemiology and Microbiology named after the honorary academician N. F. Gamaleya, 18 Gamaleya St., 123098 Moscow, Russia

National Research Center for Epidemiology and Microbiology named after the honorary academician N. F. Gamaleya, 18 Gamaleya St., 123098 Moscow, Russia

Igor A. Dyachenko , Branch of the Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 6 Nauki Avenue, 142290 Pushchino, Russia

Branch of the Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 6 Nauki Avenue, 142290 Pushchino, Russia

Gulsara A. Slashcheva , Branch of the Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 6 Nauki Avenue, 142290 Pushchino, Russia

Branch of the Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 6 Nauki Avenue, 142290 Pushchino, Russia

Elvira R. Shaykhutdinova , Branch of the Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 6 Nauki Avenue, 142290 Pushchino, Russia

Branch of the Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 6 Nauki Avenue, 142290 Pushchino, Russia

Ekaterina N. Kazakova , Branch of the Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 6 Nauki Avenue, 142290 Pushchino, Russia

Branch of the Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 6 Nauki Avenue, 142290 Pushchino, Russia

 

Elena S. Sadovnikova , Branch of the Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 6 Nauki Avenue, 142290 Pushchino, Russia

Branch of the Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 6 Nauki Avenue, 142290 Pushchino, Russia

Olga I. Patsap , Scientific and Educational Resource Center for Innovative Technologies of Immunophenotyping, Digital Spatial Profiling and Ultrastructural Analysis (Molecular Morphology), Peoples' Friendship University of Russia, Moscow, str. Miklukho-Maklaya, 6

Scientific and Educational Resource Center for Innovative Technologies of Immunophenotyping, Digital Spatial Profiling and Ultrastructural Analysis (Molecular Morphology), Peoples' Friendship University of Russia, Moscow, str. Miklukho-Maklaya, 6

Varvara V. Lebedeva , National Research Center for Epidemiology and Microbiology named after the honorary academician N. F. Gamaleya, 18 Gamaleya St., 123098 Moscow, Russia

National Research Center for Epidemiology and Microbiology named after the honorary academician N. F. Gamaleya, 18 Gamaleya St., 123098 Moscow, Russia

Arkady N. Murashev , Branch of the Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 6 Nauki Avenue, 142290 Pushchino, Russia

Branch of the Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 6 Nauki Avenue, 142290 Pushchino, Russia

Tatiana V. Grebennikova , National Research Center for Epidemiology and Microbiology named after the honorary academician N. F. Gamaleya, 18 Gamaleya St., 123098 Moscow, Russia

National Research Center for Epidemiology and Microbiology named after the honorary academician N. F. Gamaleya, 18 Gamaleya St., 123098 Moscow, Russia

References

1. Zaheer T, Pal K, Zaheer I. Topical review on nano-vaccinology: Biochemical promises and key challenges. Process Biochemistry 2021;100:237-44. https://doi.org/10.1016/j.procbio.2020.09.028 PMid:33013180 PMCid:PMC7521878

2. Tusé D, Malm M, Tamminen K, Diessner A, Thieme F, Jarczowski F, et al. Safety and immunogenicity studies in animal models support clinical development of a bivalent norovirus-like particle vaccine produced in plants. Vaccine 2022;40:977-87. https://doi.org/10.1016/j.vaccine.2022.01.009 PMid:35063285

3. Hemmati F, Hemmati-Dinarvand M, Karimzade M, Rutkowska D, Eskandari MH, Khanizadeh S, et al. Plant-derived VLP: a worthy platform to produce vaccine against SARS-CoV-2. Biotechnol Lett 2022;44:45-57. https://doi.org/10.1007/s10529-021-03211-0 PMid:34837582 PMCid:PMC8626723

4. Chernoryzh YY, Kondratieva VM, Malkova АP, Savochkina TE, Eliseeva O V., Latyshev OE, et al. Pre-clinical safety studies of intranasal virus-like particles based vaccine for prevention of COVID-19. Probl Virol 2025;70:35-46. https://doi.org/10.36233/0507-4088-278 PMid:40233335

5. Grebennikova T V., Zaykova ON, Plotnikov AA, Kostina L V., Chernoryzh YYu, Eliseeva O V., et al. A study of the safety and immunogenicity of a new vaccine for the prevention of COVID-19 based on virus-like particles in phase I clinical trials. Journal of Microbiology, Epidemiology and Immunobiology 2025;102:135-49. https://doi.org/10.36233/0372-9311-661

6. Hu B, Guo H, Zhou P, Shi Z-L. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol 2021;19:141-54. https://doi.org/10.1038/s41579-020-00459-7 PMid:33024307 PMCid:PMC7537588

7. Abdella WS, Selim AN, Diab S, Qobeia E, Elgazzar AF. Vaccination and Therapeutics, 2024, p. 165-84. https://doi.org/10.1007/978-3-031-61939-7_9 PMid:39283426

8. Filatov IE, Silaenkova MM, Tsibezov V V., Balandina M V., Norkina SN, Latyshev OE, et al. Enzyme-linked immunosorbent assay to determine the potency of a rotavirus vaccine based on virus-like particles: analytical procedure development and validation. Biological Products Prevention, Diagnosis, Treatment 2024;24:389-402. https://doi.org/10.30895/2221-996X-2024-24-4-389-402

9. Krammer F. SARS-CoV-2 vaccines in development. Nature 2020;586:516-27. https://doi.org/10.1038/s41586-020-2798-3 PMid:32967006

10. Sun L, Shen L, Fan J, Gu F, Hu M, An Y, et al. Clinical features of patients with coronavirus disease 2019 from a designated hospital in Beijing, China. J Med Virol 2020;92:2055-66. https://doi.org/10.1002/jmv.25966 PMid:32369208 PMCid:PMC7267635

11. Li Z, Xiang T, Liang B, Deng H, Wang H, Feng X, et al. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting. Front Immunol 2021;12. https://doi.org/10.3389/fimmu.2021.802858 PMid:35003131 PMCid:PMC8727357

12. Ciampi E, Uribe-San-Martin R, Soler B, García L, Guzman J, Pelayo C, et al. Safety and humoral response rate of inactivated and mRNA vaccines against SARS-CoV-2 in patients with Multiple Sclerosis. Mult Scler Relat Disord 2022;59:103690. https://doi.org/10.1016/j.msard.2022.103690 PMid:35182880 PMCid:PMC8842089

13. Akova M, Unal S. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial. Trials 2021;22:276. https://doi.org/10.1186/s13063-021-05180-1 PMid:33849629 PMCid:PMC8042350

14. Lai C-C, Chen I-T, Chao C-M, Lee P-I, Ko W-C, Hsueh P-R. COVID-19 vaccines: concerns beyond protective efficacy and safety. Expert Rev Vaccines 2021;20:1013-25. https://doi.org/10.1080/14760584.2021.1949293 PMid:34180347

15. Plotnikov AA, Zaykova ON, Rusakova E V., Grebennikova T V. Social Epidemiology: Relevance, Approaches, Main Directions and Development Trends. PUBLIC HEALTH AND LIFE ENVIRONMENT 2025:61-72. https://doi.org/10.35627/2219-5238/2025-33-1-61-72

16. Nooraei S, Bahrulolum H, Hoseini ZS, Katalani C, Hajizade A, Easton AJ, et al. Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers. J Nanobiotechnology 2021;19:59. https://doi.org/10.1186/s12951-021-00806-7 PMid:33632278 PMCid:PMC7905985

17. Hadj Hassine I, Ben M'hadheb M, Almalki MA, Gharbi J. Virus‐like particles as powerful vaccination strategy against human viruses. Rev Med Virol 2024;34. https://doi.org/10.1002/rmv.2498 PMid:38116958

18. Liu J, Dai S, Wang M, Hu Z, Wang H, Deng F. Virus like particle-based vaccines against emerging infectious disease viruses. Virol Sin 2016;31:279-87. https://doi.org/10.1007/s12250-016-3756-y PMid:27405928 PMCid:PMC7090901

19. Jeong H, Seong BL. Exploiting virus-like particles as innovative vaccines against emerging viral infections. Journal of Microbiology 2017;55:220-30. https://doi.org/10.1007/s12275-017-7058-3 PMid:28243941 PMCid:PMC7090582

20. Lua LHL, Connors NK, Sainsbury F, Chuan YP, Wibowo N, Middelberg APJ. Bioengineering virus‐like particles as vaccines. Biotechnol Bioeng 2014;111:425-40. https://doi.org/10.1002/bit.25159 PMid:24347238

21. Quan F-S, Basak S, Chu K-B, Kim SS, Kang S-M. Progress in the development of virus-like particle vaccines against respiratory viruses. Expert Rev Vaccines 2020;19:11-24. https://doi.org/10.1080/14760584.2020.1711053 PMid:31903811 PMCid:PMC7103727

22. Ledenev O V., Levitskaya O V., Syroeshkin A V. Drugs Based on Bioactive Oligopeptides. Journal of Drug Delivery and Therapeutics 2025;15:244-52. https://doi.org/10.22270/jddt.v15i6.7194

23. Nazarov AA, Ledenev OV, Petrov GV, Levitskaya OV, Syroeshkin AV. New Method of Quality and Quantity Control of the Insulin Glulisine Pharmaceuticals Based on Intrinsic Radiothermal Emission. Journal of Drug Delivery and Therapeutics 2025;15:116-25. https://doi.org/10.22270/jddt.v15i6.7189

24. Bakhrushina EO, Mikhel IB, Kondratieva VM, Zubareva IM, Kosenkova SI, Belyatskaya A V., et al. Intranasal Ion-Triggered In Situ Delivery System of Virus-like Particles: Development Using the Quality by Design Approach. Polymers (Basel) 2024;16:685. https://doi.org/10.3390/polym16050685 PMid:38475368 PMCid:PMC10935056

25. Liu H, Chen H, Yang Z, Wen Z, Gao Z, Liu Z, et al. Precision Nanovaccines for Potent Vaccination. JACS Au 2024;4:2792-810. https://doi.org/10.1021/jacsau.4c00568 PMid:39211600 PMCid:PMC11350730

26. Pulendran B, S. Arunachalam P, O'Hagan DT. Emerging concepts in the science of vaccine adjuvants. Nat Rev Drug Discov 2021;20:454-75. https://doi.org/10.1038/s41573-021-00163-y PMid:33824489 PMCid:PMC8023785

27. Petrov G V., Galkina DA, Koldina AM, Grebennikova T V., Eliseeva O V., Chernoryzh YYu, et al. Controlling the Quality of Nanodrugs According to Their New Property-Radiothermal Emission. Pharmaceutics 2024;16:180. https://doi.org/10.3390/pharmaceutics16020180 PMid:38399241 PMCid:PMC10891502

28. Rothen DA, Dutta SK, Krenger PS, Vogt A-CS, Lieknina I, Sobczak JM, et al. Preclinical Evaluation of Novel Sterically Optimized VLP-Based Vaccines against All Four DENV Serotypes. Vaccines (Basel) 2024;12:874. https://doi.org/10.3390/vaccines12080874 PMid:39204000 PMCid:PMC11359203

29. Syroeshkin A V., Petrov G V., Taranov V V., Pleteneva T V., Koldina AM, Gaydashev IA, et al. Radiothermal Emission of Nanoparticles with a Complex Shape as a Tool for the Quality Control of Pharmaceuticals Containing Biologically Active Nanoparticles. Pharmaceutics 2023;15:966. https://doi.org/10.3390/pharmaceutics15030966 PMid:36986826 PMCid:PMC10059067

30. Liu X, Min Q, Song H, Yue A, Li Q, Zhou Q, et al. Potentiating humoral and cellular immunity using a novel hybrid polymer-lipid nanoparticle adjuvant for HBsAg-VLP vaccine. J Nanobiotechnology 2023;21:441. https://doi.org/10.1186/s12951-023-02116-6 PMid:37993870 PMCid:PMC10666313

31. Kheirvari M, Liu H, Tumban E. Virus-like Particle Vaccines and Platforms for Vaccine Development. Viruses 2023;15:1109. https://doi.org/10.3390/v15051109 PMid:37243195 PMCid:PMC10223759

32. Kostina L V., Filatov IE, Eliseeva O V., Latyshev OE, Chernoryzh YYu, Yurlov KI, et al. Study of the safety and immunogenicity of VLP-based vaccine for the prevention of rotavirus infection in neonatal minipig model. Probl Virol 2023;68:415-27. https://doi.org/10.36233/0507-4088-194 PMid:38156575

33. Salmons B, Lim P-Y, Djurup R, Cardosa J. Non-clinical safety assessment of repeated intramuscular administration of an EV-A71 VLP vaccine in rabbits. Vaccine 2018;36:6623-30. https://doi.org/10.1016/j.vaccine.2018.09.062 PMid:30293762

34. Yilmaz IC, Ipekoglu EM, Bulbul A, Turay N, Yildirim M, Evcili I, et al. Development and preclinical evaluation of virus‐like particle vaccine against COVID‐19 infection. Allergy 2022;77:258-70. https://doi.org/10.1111/all.15091 PMid:34519053 PMCid:PMC8653174

35. Srinivasa Reddy Y, Narendra Babu K, Qadri SSYH, Surekha MV, Dinesh Kumar B. An innovative method of nonclinical efficacy and toxicological evaluation of recombinant Salmonella typhi Ty21a expressing HPV16 and 18 L1 proteins. MethodsX 2021;8:101219. https://doi.org/10.1016/j.mex.2021.101219 PMid:34434742 PMCid:PMC8374194

36. Pazos-Castro D, Margain C, Gonzalez-Klein Z, Amores-Borge M, Yuste-Calvo C, Garrido-Arandia M, et al. Suitability of potyviral recombinant virus-like particles bearing a complete food allergen for immunotherapy vaccines. Front Immunol 2022;13. https://doi.org/10.3389/fimmu.2022.986823 PMid:36159839 PMCid:PMC9492988

37. Petrov G V., Koldina AM, Ledenev O V., Tumasov VN, Nazarov AA, Syroeshkin A V. Nanoparticles and Nanomaterials: A Review from the Standpoint of Pharmacy and Medicine. Pharmaceutics 2025;17:655. https://doi.org/10.3390/pharmaceutics17050655 PMid:40430945 PMCid:PMC12114779

38. Go H-J, Park B-J, Ahn H-S, Han S-H, Kim D-H, Lyoo E-L, et al. Immunization with Virus-Like Particle Vaccine Protects Rabbits against Hepatitis E-3 Virus Infection. Viruses 2022;14:1432. https://doi.org/10.3390/v14071432 PMid:35891413 PMCid:PMC9322348

39. Hossain MJ, Bourgeois M, Quan F-S, Lipatov AS, Song J-M, Chen L-M, et al. Virus-Like Particle Vaccine Containing Hemagglutinin Confers Protection against 2009 H1N1 Pandemic Influenza. Clinical and Vaccine Immunology 2011;18:2010-7. https://doi.org/10.1128/CVI.05206-11 PMid:22030367 PMCid:PMC3232700

40. Pillet S, Arunachalam PS, Andreani G, Golden N, Fontenot J, Aye PP, et al. Safety, immunogenicity, and protection provided by unadjuvanted and adjuvanted formulations of a recombinant plant-derived virus-like particle vaccine candidate for COVID-19 in nonhuman primates. Cell Mol Immunol 2022;19:222-33. https://doi.org/10.1038/s41423-021-00809-2 PMid:34983950 PMCid:PMC8727235

Published

2025-08-15
Statistics
Abstract Display: 508
PDF Downloads: 333
PDF Downloads: 331

How to Cite

1.
Ledenev OV, Filatov IE, Eliseeva OV, Latyshev OE, Dyachenko IA, Slashcheva GA, et al. Toxicity Evaluation of a VLP-Based Vaccine Аgainst Human Rotavirus Infection Following a Single Administration in Rats: Serum Biochemistry and Histopathological Examination of Organs and Injection Site. J. Drug Delivery Ther. [Internet]. 2025 Aug. 15 [cited 2026 Apr. 18];15(8):69-7. Available from: https://www.jddtonline.info/index.php/jddt/article/view/7314

Issue

Vol. 15 No. 8 (2025): Volume 15, Issue 8, August 2025

Section

Research

Copyright (c) 2025 Oleg V. Ledenev , Ilya E. Filatov , Olesya V. Eliseeva , Oleg E. Latyshev , Igor A. Dyachenko , Gulsara A. Slashcheva , Elvira R. Shaykhutdinova , Ekaterina N. Kazakova , Elena S. Sadovnikova , Olga I. Patsap , Varvara V. Lebedeva , Arkady N. Murashev , Tatiana V. Grebennikova

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).

How to Cite

1.
Ledenev OV, Filatov IE, Eliseeva OV, Latyshev OE, Dyachenko IA, Slashcheva GA, et al. Toxicity Evaluation of a VLP-Based Vaccine Аgainst Human Rotavirus Infection Following a Single Administration in Rats: Serum Biochemistry and Histopathological Examination of Organs and Injection Site. J. Drug Delivery Ther. [Internet]. 2025 Aug. 15 [cited 2026 Apr. 18];15(8):69-7. Available from: https://www.jddtonline.info/index.php/jddt/article/view/7314
Crossref
Scopus
Google Scholar
Europe PMC

Most read articles by the same author(s)